Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sangustop is a **topical haemostatic agent** composed of **native absorbable collagen fibrils** designed for local haemostasis of capillary bleeding and bleeding in parenchymal organs, particularly during surgical procedures such as liver resection[1][7]. It does not contain any coagulation factors, blood serum products, or pharmaceutically active plasma components. Sangustop functions by providing a felt structure rich in surface area that facilitates the adhesion of blood platelets, thereby accelerating clot formation and haemostasis. Its mechanism is strictly physical—based on collagen-induced platelet aggregation—rather than pharmacological action. Sangustop is manufactured under the Aesculap brand, part of B. Braun, and is indicated for local haemostasis, especially in situations of diffuse oozing hemorrhage or as a supportive measure for other haemostatic techniques[1][2][3][4][5]. Preclinical and clinical studies have demonstrated rapid and reliable haemostatic efficacy, making it suitable in liver and other parenchymal organ surgeries[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sangustop.